Diffuse panbronchiolitis is an inflammatory disease affecting the respiratory bronchioles.
It causes progressive suppurative and obstructive respiratory disease.
This is an idiopathic disease which is primarily found in Japan, Korea and China.
Predisposition to the disease may be genetically-related but environmental factors should also be considered.
Failure to treat diffuse panbronchiolitis can lead to development of bronchiectasis, progressive failure and death.

Follow Up

  • Follow up & assess patient’s overall clinical response after 6 months of macrolide treatment
  • If patient shows good response w/ macrolide, eg pulmonary function, clinical, radiological findings have improved, complete the treatment for 2 years
  • If symptoms recur after stopping the treatment, resume medication
  • In patients w/ respiratory failure & extensive bronchiectasis, continue treatment for >2 years
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Respirology - Malaysia digital copy today!
Editor's Recommendations
Most Read Articles
Audrey Abella, 16 Feb 2017
Use of nonsteroidal anti-inflammatory drugs (NSAIDs) during acute respiratory infection episodes may increase the risk of acute myocardial infarction (MI), a recent study from Taiwan shows.
Pearl Toh, 01 Mar 2016
Asthma development in young children may be associated with paracetamol exposure during maternal pregnancy or infancy, a new study on the MoBa* cohort showed.
Stephen Padilla, 04 Dec 2017
About one in five (~20 percent) of lower respiratory tract illnesses (LRTIs) involve respiratory viruses irrespective of the presence of asthma exacerbation, according to a Korea study presented at the 22nd Congress of the Asian Pacific Society of Respirology (APSR) held in Sydney, Australia.
Pearl Toh, 06 Jan 2017
The experimental Ebola virus vaccine rVSV-ZEBOV shows 100 percent efficacy in protecting against the disease, assessed from day 10 onwards, according to final data from the Ebola ça Suffit!* (which translates to “Ebola that’s enough!”) trial in Guinea and Sierra Leone.